Latest News on SRPT

Financial News Based On Company


Advertisement
Advertisement

JP Morgan maintains Sarepta Therapeutics at Neutral, raises price target to $22 from $20

https://www.tradingview.com/news/tradingview:fea1d031fec81:0-jp-morgan-maintains-sarepta-therapeutics-at-neutral-raises-price-target-to-22-from-20/
JP Morgan has reiterated its "Neutral" rating for Sarepta Therapeutics (SRPT) and increased its price target to $22 from $20, marking a 10.0% hike. This new price target suggests a potential upside of 51.4% from the stock's closing price of $14.53 on November 18. Investors can find more detailed analyst ratings and forecasts for Sarepta Therapeutics on the Forecasts tab and in the News Flow section.

(SRPT) Volatility Zones as Tactical Triggers

https://news.stocktradersdaily.com/news_release/21/SRPT_Volatility_Zones_as_Tactical_Triggers_111826081002_1795050602.html
This article analyzes Sarepta Therapeutics Inc. (NASDAQ: SRPT) using AI models, identifying weak sentiment across all horizons and suggesting a short bias. It outlines three trading strategies—Position Trading (long), Momentum Breakout (breakout), and Risk Hedging (short)—with specific entry, target, and stop-loss levels. The analysis emphasizes elevated downside risk due to a lack of long-term support signals.

Sarepta won’t reopen enrollment in Duchenne gene therapy trial

https://musculardystrophynews.com/news/clinical-trial-enrollment-ends-duchenne-gene-therapy/
Sarepta Therapeutics has decided not to reopen enrollment for its Phase 3 ENVISION trial of the Duchenne muscular dystrophy gene therapy Elevidys. The trial was halted after two patient deaths from liver failure, leading Sarepta to analyze existing blinded data from 90 participants rather than recruiting more. This decision impacts future development paths for Elevidys in non-ambulatory Duchenne patients, as the FDA had previously restricted its approval to ambulatory patients.

Sarepta Therapeutics stock hits 52-week low at 14.68 USD By Investing.com

https://ca.investing.com/news/stock-market-news/sarepta-therapeutics-stock-hits-52week-low-at-1468-usd-93CH-4964523
Sarepta Therapeutics Inc. (SRPT) stock has fallen to a 52-week low of $14.68, down nearly 30% year-to-date, despite exceeding Wall Street's third-quarter 2026 earnings and revenue forecasts. The decline is attributed to weaker product sales, higher manufacturing costs, and uncertainty in its gene therapy business, leading Baird to lower its price target. However, InvestingPro analysis suggests the stock is currently undervalued.

Sarepta Therapeutics stock hits 52-week low at 14.68 USD

https://www.investing.com/news/company-news/sarepta-therapeutics-stock-hits-52week-low-at-1468-usd-93CH-5033517
Sarepta Therapeutics (SRPT) stock has fallen to a 52-week low of $14.68, representing a nearly 30% year-to-date decline and an 8% drop in the past week. Despite recent positive third-quarter earnings and revenue that surpassed Wall Street forecasts, investor concerns over weaker product sales, higher manufacturing costs, and gene therapy business uncertainty have contributed to the decline. Baird also lowered its price target for SRPT, citing near-term growth concerns for the Elevidys product.
Advertisement

Convertible notes represent 990,669 shares in AQR's Sarepta Therapeutics (SRPT) stake.

https://www.stocktitan.net/sec-filings/SRPT/schedule-13g-a-sarepta-therapeutics-inc-amended-passive-investment-di-682f564515e5.html
AQR Capital Management, LLC and AQR Capital Management Holdings, LLC have reported a beneficial ownership of 1,386,343 shares each in Sarepta Therapeutics, Inc. (SRPT), representing 1.31% of the class. This stake includes 990,669 shares attributed to convertible notes. Both entities hold shared voting and dispositive power over these shares, as detailed in their latest SCHEDULE 13G/A SEC filing.

State Street shares voting power over 7.14M Sarepta Therapeutics (SRPT) shares.

https://www.stocktitan.net/sec-filings/SRPT/schedule-13g-sarepta-therapeutics-inc-passive-investment-disclosure-5-cce1526a60a0.html
State Street Corporation has reported a 7% beneficial ownership stake in Sarepta Therapeutics, Inc. (SRPT), with shared voting power over 7,135,106 shares and shared dispositive power over 7,412,275 shares. This disclosure was made via a Schedule 13G SEC filing on November 10, 2026, for an event date of September 30, 2026. The filing identifies six State Street investment adviser subsidiaries involved in the ownership.

Sarepta Therapeutics upgraded by Deutsche Bank with a new price target

https://www.quantisnow.com/insight/sarepta-therapeutics-upgraded-by-deutsche-bank-with-a-new-price-6782809
Deutsche Bank has upgraded Sarepta Therapeutics from a Sell to a Hold rating, setting a new price target of $18.00. Historically, Sarepta's stock has shown mixed reactions to previous headlines, with a median move of 2.3% in either direction following announcements. The article also provides a history of SRPT's performance after various news events, including financial results and investor conference presentations.

Sarepta Therapeutics stock quoted at EUR 15.99 in latest indication

https://www.ad-hoc-news.de/boerse/news/corporate-news/sarepta-therapeutics-stock-quoted-at-eur-15-99-in-latest-indication/70477454
Sarepta Therapeutics stock was quoted at EUR 15.99 on Lang & Schwarz on November 7, 2026. The company specializes in neuromuscular medicines, and its latest investor relations updates include third-quarter 2026 results and other corporate developments. Investors can track real-time quotes for Sarepta Therapeutics stock.

Sarepta Therapeutics Announces Third Quarter 2026 Financial Results and Recent Corporate Developments

https://www.biospace.com/press-releases/sarepta-therapeutics-announces-third-quarter-2026-financial-results-and-recent-corporate-developments
Sarepta Therapeutics reported its third-quarter 2026 financial results, with net product revenues of $323.8 million. The company announced progress in its DM1 and FSHD programs, expecting multiple ascending dose data by year-end and preparing for Phase 3 development. Sarepta also updated its 2026 guidance, raising the lower end of total net product revenue and lowering the higher end of expenses, reflecting strong PMO performance and operating discipline.
Advertisement

Sarepta Therapeutics Q3 Earnings Call Highlights

https://www.tradingview.com/news/marketbeat:1e2956fa3094b:0-sarepta-therapeutics-q3-earnings-call-highlights/
Sarepta Therapeutics raised its 2026 product revenue forecast to $1.25 billion to $1.3 billion, despite a 13% drop in Q3 product revenue year-over-year. The company reported stable demand for its Duchenne muscular dystrophy gene therapy ELEVIDYS and continued strength in its exon-skipping drugs, with plans to submit a supplemental biologics license application for ELEVIDYS for children under age 4 next year. Sarepta also discussed its strategy for non-ambulatory patients focusing on the ENDEAVOR Cohort 8 study to mitigate acute liver injury and announced upcoming pipeline data readouts for SRP-1003 (DM1) and SRP-1001 (FSHD).

Revenue fell to $381.4M, but Sarepta Therapeutics (SRPT) narrowed its Q3 loss.

https://www.stocktitan.net/sec-filings/SRPT/10-q-sarepta-therapeutics-inc-quarterly-earnings-report-c244c42b4ded.html
Sarepta Therapeutics (SRPT) reported a narrowed net loss of $28.5 million in Q3 2026, down from $50.6 million a year prior, despite a revenue decline to $381.4 million from $399.4 million. The company's nine-month operating cash flow turned positive at $54.4 million, contrasting with a $336.7 million outflow in 2025, and it held $998.7 million in cash and investments. The revenue decrease was primarily driven by lower sales of ELEVIDYS following safety events in 2025 and a subsequent label update restricting its use to ambulatory patients.

Revenue fell 5% at Sarepta, but its 2026 forecast starts $50 million higher.

https://www.stocktitan.net/news/SRPT/sarepta-therapeutics-announces-third-quarter-2026-financial-results-3sehontfe4lj.html
Sarepta Therapeutics reported its Q3 2026 financial results, showing a 5% decrease in total revenues year-over-year to $381.4 million. Despite the revenue fall, primarily due to updated label for ELEVIDYS, the company raised the lower end of its full-year 2026 net product revenue guidance by $50 million, now expecting $1.25 billion to $1.3 billion. Sarepta also highlighted advancements in its DM1 and FSHD programs, with multiple ascending dose data anticipated by year-end 2026.

Sarepta misses on the bottom line but raises lower end of 2026 revenue guidance

https://www.tradingview.com/news/seekingalpha:4df88e35f094b:0-sarepta-misses-on-the-bottom-line-but-raises-lower-end-of-2026-revenue-guidance/
Sarepta Therapeutics reported mixed Q3 results, missing on non-GAAP EPS but beating on revenue. The company raised the lower end of its 2026 product revenue guidance to between $1.25B and $1.3B, despite a year-over-year revenue drop attributed to updated labeling for its Elevidys therapy. Shares were down in after-hours trading following the announcement.

Sarepta Therapeutics Q3 2026 Earnings Call Transcript

https://www.benzinga.com/news/26/11/62960684/sarepta-therapeutics-q3-2026-earnings-call-transcript
Sarepta Therapeutics reported Q3 2026 total net product revenue of approximately $324 million, with Elevidys contributing $83 million and the PMO franchise $240 million, leading to a raised full-year guidance of $1.25 to $1.3 billion. The company is preparing for registrational studies for its DM1 and FSHD programs, anticipating multiple ascending dose data soon, and remains financially strong to support pipeline investments. Management highlighted stabilization in Elevidys demand, continued strength in the PMO franchise, and a commitment to advancing innovative therapies while maintaining financial discipline.
Advertisement

Sarepta misses on the bottom line, but raises lower end of 2026 revenue guidance

https://seekingalpha.com/news/4667605-sarepta-misses-on-bottom-line-but-raises-lower-end-2026-revenue-guidance
Sarepta Therapeutics (SRPT) reported mixed Q3 results, missing on the bottom line but exceeding revenue expectations. The Duchenne muscular dystrophy therapy developer also increased the lower end of its full-year revenue guidance for 2026.

Sarepta Therapeutics Announces Third Quarter 2026 Financial Results and Recent Corporate Developments

https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-announces-third-quarter-2026-financial
Sarepta Therapeutics reported its third-quarter 2026 financial results, with net product revenues of approximately $323.8 million, including $240.3 million from PMO products and $83.5 million from ELEVIDYS®. The company also updated its 2026 guidance, raising the lower end of total net product revenue and lowering the higher end of expense, while advancing DM1 and FSHD programs towards late-stage development with upcoming multiple ascending dose data expected by year-end. Growing evidence reinforces ELEVIDYS' benefit-risk profile, supported by new clinical, biomarker, and real-world data.

Sarepta Therapeutics stock trades at EUR 16.96 before earnings

https://www.ad-hoc-news.de/boerse/news/corporate-news/sarepta-therapeutics-stock-trades-at-eur-16-96-before-earnings/70464063
Sarepta Therapeutics stock was trading at EUR 16.96 on Lang & Schwarz ahead of its third-quarter earnings report. The company is set to release its Q3 results after the Nasdaq close on Thursday, November 5, 2026, and management will discuss the figures in an investor conference call at 4:30 p.m. Eastern Time. Sarepta focuses on precision genetic medicines for rare diseases, including Duchenne muscular dystrophy.

Sarepta Therapeutics stock trades at EUR 16.34 on Tuesday

https://www.ad-hoc-news.de/boerse/news/corporate-news/sarepta-therapeutics-stock-trades-at-eur-16-34-on-tuesday/70450727
Sarepta Therapeutics stock traded at EUR 16.34 on Lang & Schwarz on Tuesday, November 3, 2026. The company's investor communications are in focus, with upcoming announcements on investor conferences and third-quarter results. These disclosures are expected to provide new information on the company's operating progress and its rare-disease portfolio.

Sarepta Therapeutics, Inc. (SRPT) Stock Price, News, Quote & History

https://ca.finance.yahoo.com/quote/SRPT/latest-news/
This article provides a snapshot of Sarepta Therapeutics, Inc. (SRPT) stock information, including its real-time price, recent trading activity, and a compilation of news headlines related to the company. The news covers various topics such as comparisons with other biotech firms, earnings previews, analyst expectations, and updates on pipeline setbacks and successes. The content also includes market data for several indices and commodities.
Advertisement

Sarepta Therapeutics, Inc. (SRPT) Seasonal Returns Chart - Yahoo Finance

https://ca.finance.yahoo.com/quote/SRPT/seasonality/
The article provides a seasonal returns chart for Sarepta Therapeutics, Inc. (SRPT), detailing the average monthly price return between 2016 and 2026. It also includes current stock information, showing a slight increase in after-hours trading after a drop during regular market hours.

Sarepta Therapeutics (SRPT) Nears Earnings With Elevidys In Focus On Whether Shares Are Fully Valued

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-srpt/sarepta-therapeutics/news/sarepta-therapeutics-srpt-nears-earnings-with-elevidys-in-fo
Sarepta Therapeutics (SRPT) is approaching its Q3 earnings release on November 5, with analysts expecting higher quarterly earnings but lower revenue. Despite a recent 25% share price rebound over 90 days, its year-to-date and multi-year returns show significant declines, raising questions about its valuation. The company's Elevidys therapy is a key focus, especially regarding safety concerns and potential for wider market adoption, with Simply Wall St's narrative suggesting the stock is currently 14% undervalued.

H.C. Wainwright Maintains Sarepta Therapeutics(SRPT.US) With Sell Rating, Maintains Target Price $5

https://www.moomoo.com/news/post/1003022753/hc-wainwright-maintains-sarepta-therapeutics-srptus-with-sell-rating-maintains
H.C. Wainwright has reiterated its Sell rating on Sarepta Therapeutics (SRPT.US), maintaining a target price of $5. This decision reflects the firm's ongoing outlook on the company's financial and operational prospects.

SRPT Q3'26 Earnings: revenue estimate is 352.20M USD

https://www.tradingview.com/news/tradingview:5fc5121400bd4:0-srpt-q3-26-earnings-revenue-estimate-is-352-20m-usd/
Sarepta Therapeutics, Inc. (SRPT) is scheduled to announce its Q3'26 earnings on November 5, after market close, at 4:05 PM ET (9:05 PM UTC). Analysts estimate revenue for Q3'26 to be $352.20 million USD, with an anticipated EPS of $0.07 USD. The article includes a table comparing reported and estimated revenue and EPS for recent quarters.

Trading Systems Reacting to (SRPT) Volatility

https://news.stocktradersdaily.com/news_release/20/Trading_Systems_Reacting_to_SRPT_Volatility_102926095002_1793325002.html
This article analyzes Sarepta Therapeutics Inc. (NASDAQ: SRPT) volatility, indicating strong near and mid-term sentiment but a weak long-term outlook. It highlights a mid-channel oscillation pattern and presents three AI-generated institutional trading strategies tailored for different risk profiles, along with multi-timeframe signal analysis. The report also notes an exceptional 65.0:1 risk-reward setup targeting an 18.1% gain versus 0.3% risk.
Advertisement

Price to earnings forward of Sarepta Therapeutics, Inc. – LS:A1J1BH

https://www.tradingview.com/symbols/LS-A1J1BH/financials-statistics-and-ratios/price-earnings-fwd/
This article provides a brief financial overview of Sarepta Therapeutics, Inc. (A1J1BH) focusing on its forward price-to-earnings ratio. It indicates that the market for this stock was closed with no trades. The content is primarily a financial data point from TradingView, referencing market data from ICE Data Services and FactSet.

TD Cowen keeps USD 17 target for Sarepta Therapeutics stock

https://www.ad-hoc-news.de/boerse/news/corporate-news/td-cowen-keeps-usd-17-target-for-sarepta-therapeutics-stock/70420207
TD Cowen has maintained its USD 17.00 price target for Sarepta Therapeutics (SRPT) stock. This decision follows Sarepta's second-quarter results, which reported revenue of USD 401.25 million and a GAAP net loss of USD 4.89 million. Investors are now looking forward to the company's third-quarter results, scheduled for release on November 5, 2026, which will provide further insights into product demand and the development pipeline.

Sarepta executives will appear at conferences in New York and Boston on Nov. 9.

https://www.stocktitan.net/news/SRPT/sarepta-therapeutics-to-present-at-upcoming-investor-ugw10r8mqveq.html
Sarepta Therapeutics announced that senior management will participate in two investor conferences on November 9, 2026: the 8th Annual Wolfe Research Healthcare Conference in New York City and the Guggenheim Securities 3rd Annual Healthcare Innovation Conference in Boston. A fireside chat at the Guggenheim conference will be webcast live on Sarepta’s investor relations website. The company, a leader in precision genetic medicine for rare diseases, encourages investors to regularly consult its website for important information.

Wedbush Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $35

https://www.moomoo.com/news/post/1002349753/wedbush-maintains-sarepta-therapeutics-srptus-with-buy-rating-maintains-target
Wedbush has reiterated its Buy rating on Sarepta Therapeutics (SRPT.US) and maintained its target price at $35. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance and valuation.

How Investors May Respond To Sarepta Therapeutics (SRPT) DM1 Therapy Progress

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-srpt/sarepta-therapeutics/news/how-investors-may-respond-to-sarepta-therapeutics-srpt-dm1-t
Sarepta Therapeutics (SRPT) recently announced promising preclinical data for SRP-1003 in myotonic dystrophy type 1, demonstrating a dose-dependent reduction of pathogenic DMPK transcripts. This progress supports the company's RNA and gene therapy platform and its strategy to diversify beyond Duchenne muscular dystrophy. While the near-term focus remains on ELEVIDYS execution, SRP-1003's advancement offers a potential long-term growth driver, particularly as analysts currently forecast declining revenue for Sarepta over the next three years.
Advertisement

Sarepta Therapeutics to Present at Upcoming Investor Conferences - October 26, 2026

https://www.biospace.com/press-releases/sarepta-therapeutics-to-present-at-upcoming-investor-conferences-october-26-2026
Sarepta Therapeutics, Inc. announced that senior management will participate in two investor conferences on November 9, 2026: the 8th Annual Wolfe Research Healthcare Conference in New York City and the Guggenheim Securities 3rd Annual Healthcare Innovation Conference in Boston, where a fireside chat will be held at 3 p.m. ET. A live webcast of the Guggenheim conference presentation will be available on Sarepta's investor relations website and archived for 90 days. The company focuses on precision genetic medicine for rare diseases, particularly Duchenne muscular dystrophy, and is developing programs across muscle, central nervous system, and cardiac diseases.

Sarepta schedules third-quarter results. TD Cowen targets Sarepta Therapeutics stock at USD 17

https://www.ad-hoc-news.de/boerse/news/corporate-news/sarepta-schedules-third-quarter-results-td-cowen-targets-sarepta-therapeutics-stock-at-usd-17/70408953
Sarepta Therapeutics has scheduled its third-quarter 2026 results for November 5, 2026, after the Nasdaq close. The company reported second-quarter revenue of USD 401.25 million, with consensus expecting USD 352.20 million for the third quarter. TD Cowen maintained a Hold rating and a USD 17.00 price target on the stock, while the upcoming report will also provide updates on the company's siRNA pipeline, including SRP-1003 data for myotonic dystrophy type 1.

Sarepta Therapeutics, Inc. (SRPT) stock price, news, quote and history

https://au.finance.yahoo.com/quote/SRPT/
Sarepta Therapeutics, Inc. (SRPT) stock closed at $17.73, down 2.48%, with after-hours trading showing no change. The company, a commercial-stage biopharmaceutical firm, focuses on RNA-targeted therapeutics, gene therapy, and other genetic modalities for rare diseases, offering treatments like EXONDYS 51 and ELEVIDYS for Duchenne muscular dystrophy. Despite recent negative returns, its 3-year and 5-year returns have outperformed the S&P 500.

Sarepta Therapeutics, Inc. Estimates – NASDAQ:SRPT

https://www.tradingview.com/symbols/NASDAQ-SRPT/financials-estimates/
This article provides an overview of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) financial data and analyst estimates on TradingView. It allows users to explore reported financial data and analyst estimates across various financial statements and valuation metrics. The platform enables comparison of actual results with average, high, and low estimates, and visualization of trends over time.

Is Sarepta Therapeutics (SRPT) Undervalued Following New SRP 1003 Preclinical Data?

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-srpt/sarepta-therapeutics/news/is-sarepta-therapeutics-srpt-undervalued-following-new-srp-1
Sarepta Therapeutics (SRPT) recently released new preclinical data for its SRP-1003 program for myotonic dystrophy type 1, highlighting its RNA-targeted pipeline. Despite a 12.9% year-to-date decline, the stock has gained 16.9% over the past 90 days. The company is considered modestly undervalued with a narrative fair value of $21.73, and is self-funding its pipeline work through its cash-flow positive Duchenne muscular dystrophy portfolio.
Advertisement

Is Sarepta Therapeutics (SRPT) Undervalued Following New SRP 1003 Preclinical Data?

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-srpt/sarepta-therapeutics/news/is-sarepta-therapeutics-srpt-undervalued-following-new-srp-1/amp
Sarepta Therapeutics (SRPT) recently released new preclinical data for its SRP-1003 program for myotonic dystrophy type 1, highlighting its RNA-targeted pipeline. Despite a 12.9% year-to-date decline, the stock has gained 16.9% over the past 90 days. The company is considered 15% undervalued with a narrative fair value of $21.73, leveraging its Duchenne muscular dystrophy portfolio to fund pipeline development.

Sarepta Therapeutics to Announce Third Quarter 2026 Financial Results

https://www.financialcontent.com/article/bizwire-2026-10-22-sarepta-therapeutics-to-announce-third-quarter-2026-financial-results
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) will announce its third quarter 2026 financial results after the Nasdaq Global Market closes on Thursday, November 5, 2026. Following the announcement, the company will host a conference call at 4:30 p.m. ET to discuss the results, which will be webcast live on Sarepta's investor relations website. A replay of the event will be archived online for one year.

H.C. Wainwright keeps USD 5 target for Sarepta Therapeutics stock

https://www.ad-hoc-news.de/boerse/news/nebenwerte/h-c-wainwright-keeps-usd-5-target-for-sarepta-therapeutics-stock/70373769
H.C. Wainwright has reiterated a Sell rating and a USD 5.00 price target for Sarepta Therapeutics (SRPT) stock, despite the company's second-quarter 2026 revenue of USD 401.25 million. This bearish outlook contrasts with a consensus Reduce rating and an average 12-month target of USD 22.59 from 21 other firms. The debate among analysts centers on the stabilization of ELEVIDYS demand and the potential of Sarepta's siRNA pipeline.

Lobbying Update: $160,000 of SAREPTA THERAPEUTICS INC. lobbying was just disclosed

https://www.quiverquant.com/news/Lobbying+Update%3A+%24160%2C000+of+SAREPTA+THERAPEUTICS+INC.+lobbying+was+just+disclosed
SAREPTA THERAPEUTICS INC. (SRPT) recently disclosed $160,000 in lobbying expenditures for Q3 2026, covering issues such as appropriations, pediatric disease programs, patient access, and emerging biotechnology policy. The article also details recent hedge fund activity in SRPT stock, showing both increases and decreases in institutional holdings, and provides recent analyst price targets for the company.

Sarepta Therapeutics Inc (AB3A.SG) stock price, news, quote and history

https://uk.finance.yahoo.com/quote/AB3A.SG/sec-filing/
This Yahoo Finance page provides an overview of Sarepta Therapeutics Inc (AB3A.SG), including its stock price, news, charts, and historical data. As of the close on October 20, 2026, the stock was trading at 16.94 EUR, up 7.35%. The article also presents performance overview data, comparing AB3A.SG's trailing total returns against the S&P 500 benchmark.
Advertisement

H.C. Wainwright Maintains Sarepta Therapeutics(SRPT.US) With Sell Rating, Maintains Target Price $5

https://www.moomoo.com/news/post/1001576837/hc-wainwright-maintains-sarepta-therapeutics-srptus-with-sell-rating-maintains
H.C. Wainwright has reiterated its Sell rating for Sarepta Therapeutics (SRPT.US) and maintained a target price of $5. This decision reflects the firm's ongoing outlook on the pharmaceutical company's prospects.

The Technical Signals Behind (SRPT) That Institutions Follow

https://news.stocktradersdaily.com/news_release/150/The_Technical_Signals_Behind_SRPT_That_Institutions_Follow_101926081402_1792455242.html
This article analyzes the technical signals for Sarepta Therapeutics Inc. (NASDAQ: SRPT), highlighting strong near-term sentiment challenging persistent mid and long-term weakness. It identifies resistance testing, suggesting a potential short setup with a significant risk-reward ratio, and outlines three distinct AI-generated trading strategies for various risk profiles. The piece also provides multi-timeframe signal analysis and lists recent related articles.

H.C. Wainwright reiterates Sarepta stock Sell rating at $5 target

https://www.investing.com/news/analyst-ratings/hc-wainwright-reiterates-sarepta-stock-sell-rating-at-5-target-93CH-4957469
H.C. Wainwright has reiterated a Sell rating on Sarepta Therapeutics (NASDAQ:SRPT) with a $5.00 price target, despite InvestingPro data suggesting the stock might be undervalued. The firm's decision follows Sarepta's data announcement regarding DMPK knockdown, but H.C. Wainwright sees no basis to increase approval probability for SRP-1003. While Sarepta was not profitable in the last year, analysts predict profitability for the current year.

Sarepta presents 80 percent DM1 data for Sarepta Therapeutics stock

https://www.ad-hoc-news.de/boerse/news/nebenwerte/sarepta-presents-80-percent-dm1-data-for-sarepta-therapeutics-stock/70353360
Sarepta Therapeutics has presented promising preclinical data for SRP-1003, showing up to 80% knockdown of disease-causing DMPK RNA, a key driver of myotonic dystrophy type 1. This experimental treatment demonstrated biological activity in critical cellular compartments and sustained impact in animal studies, with a Phase 1/2 trial now underway. Despite a cautious "Hold" rating and a recent revenue decline, the company maintains a $1.8 billion market capitalization, with its next earnings report scheduled for November 2, 2026, serving as a crucial checkpoint for investors to evaluate pipeline progress against commercial performance.

DM1 RNA Knockdown Data Might Change The Case For Investing In Sarepta Therapeutics Stock

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-srpt/sarepta-therapeutics/news/dm1-rna-knockdown-data-might-change-the-case-for-investing-i
Sarepta Therapeutics (SRPT) has released promising preclinical data for SRP-1003, an investigational siRNA for myotonic dystrophy type 1, showing an 80% reduction of pathogenic DMPK RNA. This data suggests direct nuclear engagement, potentially diversifying Sarepta beyond its Duchenne muscular dystrophy franchise. While the Duchenne franchise remains key for cash flow, the siRNA platform, bolstered by SRP-1003 and SRP-1001 data, is emerging as a strong second pillar for long-term growth.
Advertisement

Sarepta Therapeutics (SRPT) Could Be 22% Undervalued Following SRP 1003 Preclinical Data

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-srpt/sarepta-therapeutics/news/sarepta-therapeutics-srpt-could-be-22-undervalued-following/amp
Sarepta Therapeutics (SRPT) recently released fresh preclinical data for its SRP-1003 program, demonstrating significant knockdown of pathogenic DMPK RNA in myotonic dystrophy type 1 models. Despite the positive data, the stock has experienced a recent downturn, falling 19.6% in 30 days and 21.0% year-to-date, making it appear 22% undervalued compared to an estimated fair value of $21.73. This valuation hinges on the continued success and safety of its Duchenne franchise and new RNA programs, with potential risks tied to ELEVIDYS safety data and infusion logistics.

Sarepta presents DM1 data as Sarepta Therapeutics stock trades at EUR 15.03

https://www.ad-hoc-news.de/boerse/news/nebenwerte/sarepta-presents-dm1-data-as-sarepta-therapeutics-stock-trades-at-eur/70329779
Sarepta Therapeutics (SRPT) presented new preclinical data for SRP-1003, showing up to 80% knockdown of pathogenic DMPK messenger RNA for myotonic dystrophy type 1, with sustained exposure for up to 16 weeks after a single dose. This pipeline update provides a new focus beyond their Duchenne muscular dystrophy franchise, as the company reported weaker sales but strong adjusted earnings in Q2 2026. The stock was trading at EUR 15.03 on October 15, 2026, with a market capitalization of USD 1.8 billion.

Sarepta Therapeutics Presents New Preclinical Data Demonstrating Robust Knockdown of Pathogenic DMPK RNA in the Nucleus with SRP-1003 in DM1 at 2026 Oligonucleotide Therapeutics Society Annual Meeting

https://www.biospace.com/press-releases/sarepta-therapeutics-presents-new-preclinical-data-demonstrating-robust-knockdown-of-pathogenic-dmpk-rna-in-the-nucleus-with-srp-1003-in-dm1-at-2026-oligonucleotide-therapeutics-society-annual-meeting
Sarepta Therapeutics presented new preclinical data for SRP-1003, an investigational siRNA for myotonic dystrophy type 1 (DM1), showing robust knockdown of pathogenic DMPK RNA in both the nucleus and cytoplasm. The data, presented at the 22nd Annual Meeting of the Oligonucleotide Therapeutics Society, demonstrated up to 80% knockdown in each compartment and functional correction of MBNL-dependent mis-splicing. These findings support SRP-1003's potential to address the underlying pathology of DM1 by targeting toxic RNA in the nucleus and advancing its ongoing Phase 1/2 clinical study.

Sarepta Therapeutics Presents New Preclinical Data Demonstrating Robust Knockdown of Pathogenic DMPK RNA in the Nucleus with SRP-1003 in DM1 at 2026 Oligonucleotide Therapeutics Society Annual Meeting

https://finance.yahoo.com/healthcare/articles/sarepta-therapeutics-presents-preclinical-data-123000356.html
Sarepta Therapeutics (NASDAQ: SRPT) announced new preclinical data for SRP-1003, their investigational siRNA program for Myotonic Dystrophy Type 1 (DM1), at the 22nd Annual Meeting of the Oligonucleotide Therapeutics Society. The data showed that SRP-1003 effectively reduced pathogenic DMPK RNA in the nucleus, where the disease pathology originates, achieving up to 80% knockdown in preclinical models. This nuclear activity was confirmed by multiple methods, providing strong functional evidence and supporting the advancement of SRP-1003 in its ongoing Phase 1/2 clinical study.

Sarepta Therapeutics Presents New Preclinical Data Demonstrating Robust Knockdown of Pathogenic DMPK RNA in the Nucleus with SRP-1003 in DM1 at 2026 Oligonucleotide Therapeutics Society Annual Meeting

https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-presents-new-preclinical-data-demonstrating
Sarepta Therapeutics presented new preclinical data at the 22nd Annual Meeting of the Oligonucleotide Therapeutics Society (OTS), highlighting that its investigational siRNA program, SRP-1003, for myotonic dystrophy type 1 (DM1), effectively reduces pathogenic DMPK transcripts within the nucleus. The data showed SRP-1003 achieved up to approximately 80% knockdown of pathogenic DMPK mRNA in both the cytoplasm and nucleus in a dose-dependent manner, confirming nuclear activity through multiple independent methodologies. These findings strengthen the biological rationale for SRP-1003 and support its continued advancement in an ongoing Phase 1/2 clinical study.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement